Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Flexion Therapeutics Inc announces positive topline results from phase 2a pharmacokinetic trial with lead compound FX006


Tuesday, 17 Jun 2014 04:10pm EDT 

Flexion Therapeutics Inc:Says positive topline clinical trial results from Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks.FX006 is Flexion's non-opioid, sustained-release, IA formulation of TCA.It is designed to provide prolonged pain relief for the treatment of osteoarthritis (OA) of the knee, while potentially avoiding untoward systemic effects associated with immediate-release steroids. 

Company Quote

26.32
1.76 +7.17%
4:00pm EDT